[Highlight] What Happens to Society When We Live to 100? with Celine Halioua

What It Covers

Celine Halioua, CEO of Loyal, discusses longevity's shift from supplements to FDA-approved drugs, the societal restructuring required when humans routinely live past 100, and how cognitive aging drugs could reshape cultural flexibility.

Key Questions Answered

• •FDA Drug Approval as Inflection Point: Longevity remains associated with supplements and biometric optimization rather than medicine. The first FDA-approved lifespan-extension drug will reframe aging as a treatable pathological process, separating physiological decline from chronological age as a measurable, intervenable condition.
• •Realistic Lifespan Targets: Radical extension to hundreds of years requires interventions of extreme complexity with unclear near-term trade-offs. A more grounded framework: current long-tail outcomes, such as cognitively sharp 115-year-olds in isolated populations, becoming statistically common rather than exceptional across the general population.
• •Cognitive Aging Drugs and Social Flexibility: Drugs targeting cognitive aging could reduce the neurological crystallization of beliefs and preferences that hardens with age. This matters beyond music taste — it could increase an aging population's capacity to update worldviews, reducing generational ideological rigidity at a societal scale.
• •Longevity as Socioeconomic Equalizer: Healthier parents for longer reduces the caretaking burden that forces lower-income individuals to forgo career mobility. Halioua frames parental illness as a structural limiter on economic advancement, one that longevity medicine could partially dissolve by extending the window of parental independence.